![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page1544.jpg)
Conclusions
• IMRT is now an accepted standard for LA NSCLC
radiotherapy
• Specific dose-constraints on low doses should be
adopted
• Ongoing trials will clarify us the role of PET-guided hypo-
fractionated boost and the best chemotherapy
combination
• New drugs will hopefully amplify the benefit of the
combined modality approach